The Science
Behind the Supply

Radiochemistry is what enables isotope production to meet the standards required for clinical development, commercial use, and the separation, purification, and preparation required to deliver a usable medical product.

Niowave has built this capability in-house over time, beginning with Molybdenum-99 and expanding through Yttrium-90 to Actinium-225, each program adding to the depth of knowledge in isotope production, separation chemistry, and radioactive materials handling. In a field where established methods are limited and practical expertise is difficult to acquire, that experience has shaped processes designed to deliver consistent purity, reliable yields, and a quality profile that performs as required across clinical and commercial applications.

Our expertise also underpins our ability to handle the raw materials that make Actinium-225 production possible. Radium, the parent material for Ac-225, is a globally constrained resource that requires careful handling, purification, and processing before it ever enters an accelerator. Niowave’s radiochemistry team manages this process from acquisition through production, ensuring that the integrity of the supply chain begins at the very first step.

One of the most tangible expressions of Niowave’s integrated capabilities is our radium acquisition program. Radium is not available through conventional supply channels. Acquiring it requires radiation safety expertise, international regulatory knowledge, and specialized logistics to properly manage and transport a highly controlled material.

Niowave has built all its radium capabilities internally from accelerator operations to radiochemistry to compliance, making us one of the few organizations in the world positioned to conduct radium recovery missions responsibly and effectively. We have completed missions across multiple countries, recovering legacy radium sources left unmanaged for decades, converting them into the raw material for Actinium-225 production.

Our radium acquisition program could not exist without the accelerator infrastructure to utilize material, radiochemistry expertise to process it, or the compliance framework to handle and transport it legally and safely. It is a clear example of how Niowave’s unique competencies compound, with each enabling the rest to create something that would not be possible alone.

Niowave’s accelerator technology, radiochemistry, and production capabilities have been developed together over time, built through sustained, focused work. This work has created a depth of experience and understanding that continues to shape how we design, operate, and refine our process.

This foundation supports a differentiated approach to isotope production, enabling consistent performance as we scale and adapt to the evolving needs of targeted alpha therapy.